HMHygon Mutavhatsindi

Hygon Mutavhatsindi

*This is an algorithmically generated author record based on publicly available information.

Hygon Mutavhatsindi has a total of 129 co-authors. Here are the top co-authors by number of shared publications:

  • Catherine Riou

    Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa

    4 shared publications
  • Kim Stanley

    Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, P.O. Box 241, Cape Town 8000, South Africa; South African Medical Research Council Centre for Tuberculosis Research, Cape Town 8000, South Africa; DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, P.O. Box 241, Cape Town 8000, South Africa

    4 shared publications
  • Novel Njweipi Chegou

    Stellenbosch University, South Africa

    4 shared publications
  • Candice I. Snyders

    Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, P.O. Box 241, Cape Town 8000, South Africa; South African Medical Research Council Centre for Tuberculosis Research, Cape Town 8000, South Africa; DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, P.O. Box 241, Cape Town 8000, South Africa

    3 shared publications
  • Ntombi Benede

    Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa

    3 shared publications
  • Penny L. Moore

    SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand

    3 shared publications

Latest Publications

  • Open Access

    Commentary: Increased circulating Th17 cells and altered CD4 T cell maturation and differentiation in active tuberculosis with type 2 diabetes: a pilot study

    by Hygon Mutavhatsindi, Muki Shey

    The co-epidemic of tuberculosis (TB) and type 2 diabetes mellitus (T2DM) remains one of the major barriers to global TB eradication. T2DM triples the risk of developing active TB (1), complicates treatment, and is associated with delayed cure and increased mortality (2,3).While epidemiological studies have long defined the clinical scope of this syndemic, the precise immunological mechanisms remain unclear. A recent pilot study by Ogongo and colleagues (4) provides compelling cellular-level insight into this issue, reporting increased frequencies of circulating Th17 cells and altered total CD4 T cell maturation and differentiation in active TB patients with T2DM. Their findings call for a shift in perspective, recognizing T2DM not merely as a metabolic comorbidity but as an active immunomodulatory condition with major implications for TB pathogenesis, diagnosis, and host-directed therapy (HDT).Protective immunity against Mycobacterium tuberculosis (M. tuberculosis) is essential and relies on a successful, sustained T helper 1 (Th1) response. The Th1 axis, driven by Interferon-γ (IFN-γ), is essential for macrophage activation and the formation of the granuloma, the structure responsible for containing latent infection.The observation that T2DM leads to altered CD4 T cell maturation and differentiation is arguably the most impactful finding from a public health perspective, as it offers a molecular mechanism for the increased risk of latent TB infection (LTBI) progression to active TB. Sustained latency relies on a population of durable, highly functional Th1 memory T cells (5,6). The diabetic microenvironment, characterized by chronic hyperglycaemia and systemic inflammation, fundamentally disrupts T-cell immunometabolism (7). T cells exposed to chronic hyperglycaemia become increasingly glycolysis-dependent, a metabolic state that favours dysfunctional differentiation trajectories and can promote exhaustion phenotypes (8). Studies have shown that antigen-specific T-cell responses are diminished in latent TB coinfected with T2DM (8-10).If T2DM compromises the terminal differentiation and survival of these protective Th1 memory cells, the immune surveillance required to contain dormant bacilli within the granuloma is critically impaired. The failure to maintain a high-quality, long-lived Th1 population suggests a permissive immunological environment that facilitates M. tuberculosis reactivation, directly connecting the metabolic status of the host to the failure of adaptive immunity to maintain latency. It is important to note that the immunological profiles characterized in the pilot study by Ogongo and colleagues represent total circulating CD4+ T-cell phenotypes rather than M. tuberculosis-specific or lung-resident populations. While these peripheral markers provide valuable insights into systemic immune dysregulation in T2DM, they may not fully reflect the antigen-specific responses or the localized inflammatory landscape within the lung parenchyma.Immune Deviation: Th17 and the Failure to CureIn active TB, the prognosis in T2DM patients is consistently worse, characterized by delayed sputum conversion, higher rates of treatment failure, and increased tissue damage (2,3). The observed pathological shift toward increased frequencies of circulating Th17 cells provides a systemic biological correlate for these adverse clinical outcomes (2,3).However, the role of Th17 cells in TB is complex and context-dependent. While early Th17mediated responses are essential for mucosal immunity and the initial recruitment of protective neutrophils to the site of infection, the efficacy of this axis follows a "Goldilocks" principle where both deficiency and excess of IL-17 can lead to clinical detriment (11). In the context of active tuberculosis-diabetes mellitus (TB-DM), the observed Th17 expansion appears to be a detrimental immune deviation rather than an effective protective response.Chronic, misdirected inflammation driven by IL-17 is strongly associated with the matrix metalloproteinase (MMP) cascade, including heightened MMP-9 and MMP-1 activity often observed in T2DM, which is the central driver of cavitary, destructive lung disease. We posit that the chronic metabolic inflammation inherent to T2DM serves as a pathological driver that shifts the Th17 response away from its protective homeostatic baseline toward the hyper-inflammatory, maladaptive phenotype reported by Ogongo and colleagues. The excessive tissue pathology seen in TB-DM co-infection, often leading to permanent lung damage and functional decline is thus explained not by a lack of inflammation, but by an inappropriate type of inflammation.Furthermore, this deviation skews the T-cell differentiation landscape toward the Th17 lineage, often at the expense of the protective Th1 lineage. These findings suggest that T2DM may exert a dual detrimental effect, potentially attenuating the Th1-mediated protective response while amplifying Th17-driven inflammatory pathology. This overall imbalance between impaired Th1 immunity and exaggerated Th17 inflammation in TB-DM is summarized conceptually in Figure 1.These findings transition T2DM in the context of TB from a passive comorbidity to an active immune-metabolic disorder that detrimentally programs the host immune response (3,7). This perspective demands a strategic pivot in therapeutic design (12):If hyperglycaemia and associated metabolic stress are driving T-cell dysfunction, then intensive, individualized glycaemic control must be viewed as an indispensable form of HDT for TB-DM patients (12). We must move beyond simply monitoring HbA1c to ensuring that acute metabolic fluctuations are minimized, thereby reducing the environmental cues that favour Th17 differentiation and T-cell exhaustion.The immunomodulatory effects of established DM medications must be systematically investigated. Drugs like Metformin have known pleiotropic effects on T-cell metabolism, potentially...

  • Open Access

    Circulating MicroRNA Profiles in Pregnant South African Women with Different Types of Diabetes Mellitus

    by Matladi Masete, Stephanie Dias, Nompumelelo Malaza, Sumaiya Adam, Hygon Mutavhatsindi, Carmen Valverde-Tercedor, Begoña Vega-Guedes, Ana Maria Wägner, Carmen Pheiffer

    Diabetes in pregnancy increases the risk of adverse perinatal outcomes for mother and child, with severity influenced by the type of diabetes and degree of hyperglycemia. This study aimed to identify circulating microRNAs (miRNAs) associated with different types of diabetes in pregnancy. Serum miRNAs were profiled in pregnant South African women with type 1 diabetes (T1DM), type 2 diabetes (T2DM), gestational diabetes (GDM), and normoglycemia using PCR arrays (n = 15). Differentially expressed miRNAs were validated in pregnant South African women (n = 167), and a separate cohort of Spanish pregnant women with T1DM and T2DM (n = 48). PCR arrays showed significant differential expression for miR-19b-3p (↓ 9.8-fold; p = 0.033) in GDM, miR-20a-5p (↓ 4.5-fold; p = 0.047) in T1DM, and miR-29a-3p (↑ 1.8-fold; p = 0.002) in T2DM compared to normoglycemia. Screening in the larger cohort showed lower expression of miR-20a-5p (↓ 2-fold; p = 0.013) in GDM and miR-30d-5p (↓ 2.1-fold; p = 0.032) in T1DM compared to normoglycemia. Additionally, miR-20a-5p levels were higher in women with T2DM compared to those with GDM (↑ 2.5-fold; p = 0.019). Our findings show that miRNA profiles are largely consistent across different types of diabetes in pregnancy, suggesting that hyperglycemia plays a key role in shaping miRNA expressions. Moreover, the identification of several shared gene targets suggests common underlying pathophysiological mechanisms.


  • Open Access

    Baseline and end-of-treatment host serum biomarkers predict relapse in adults with pulmonary tuberculosis

    by Hygon Mutavhatsindi, Charles M. Manyelo, Candice I. Snyders, Ilana Van Rensburg, Martin Kidd, Kim Stanley, Gerard Tromp, Reynaldo Dietze, Bonnie Thiel, Paul D. van Helden, et al.


  • Open Access

    Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants

    by Catherine Riou, Jinal N. Bhiman, Yashica Ganga, Shobna Sawry, Frances Ayres, Richard Baguma, Sashkia R. Balla, Ntombi Benede, Mallory Bernstein, Asiphe S. Besethi, et al.

    We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 infection. A total of 286 adults (with or without HIV) were enrolled >4 months after an Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of Ad26.COV2.S or BNT162b2 vaccine. B cell responses (binding, neutralization and antibody dependent cellular cytotoxicity-ADCC), and spike-specific T-cell responses were evaluated at baseline, 2, 12 and 24 weeks post-boost. Antibody and T-cell immunity targeting the Ad26 vector was also evaluated. No vaccine-associated serious adverse events were recorded. The full- and half-dose BNT162b2 boosted anti-SARS-CoV-2 binding antibody levels (3.9- and 4.5-fold, respectively) and neutralizing antibody levels (4.4- and 10-fold). Binding and neutralizing antibodies following half-dose Ad26.COV2.S were not significantly boosted. Full-dose Ad26.COV2.S did not boost binding antibodies but slightly enhanced neutralizing antibodies (2.1-fold). ADCC was marginally increased only after a full-dose BNT162b2. T-cell responses followed a similar pattern to neutralizing antibodies. Six months post-boost, antibody and T-cell responses had waned to baseline levels. While we detected strong anti-vector immunity, there was no correlation between anti-vector immunity in Ad26.COV2.S recipients and spike-specific neutralizing antibody or T-cell responses post-Ad26.COV2.S boosting. Overall, in the context of hybrid immunity, boosting with heterologous full- or half-dose BNT162b2 mRNA vaccine demonstrated superior immunogenicity 2 weeks post-vaccination compared to homologous Ad26.COV2.S, though rapid waning occurred by 12 weeks post-boost. Trial Registration: The study has been registered to the South African National Clinical Trial Registry (SANCTR): DOH-27-012022-7841. The approval letter from SANCTR has been provided in the up-loaded documents.


  • Open Access

    Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants

    by Catherine Riou, Jinal N Bhiman, Yashica Ganga, Shobna Sawry, Frances Ayres, Richard Baguma, Sashkia R Balla, Ntombi Benede, Mallory Bernstein, Asiphe S Besethi, et al.

    Background We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 infection. Methods A total of 286 adults (with or without HIV) were enrolled >4 months after an Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of Ad26.COV2.S or BNT162b2 vaccine. B cell responses (binding, neutralization and antibody dependent cellular cytotoxicity-ADCC), and spike-specific T-cell responses were evaluated at baseline, 2, 12 and 24 weeks post-boost. Antibody and T-cell immunity targeting the Ad26 vector was also evaluated. Results No vaccine-associated serious adverse events were recorded. The full- and half-dose BNT162b2 boosted anti-SARS-CoV-2 binding antibody levels (3.9- and 4.5-fold, respectively) and neutralizing antibody levels (4.4- and 10-fold). Binding and neutralizing antibodies following half-dose Ad26.COV2.S were not significantly boosted. Full-dose Ad26.COV2.S did not boost binding antibodies but slightly enhanced neutralizing antibodies (2.1-fold). ADCC was marginally increased only after a full-dose BNT162b2. T-cell responses followed a similar pattern to neutralizing antibodies. Six months post-boost, antibody and T-cell responses had waned to baseline levels. While we detected strong anti-vector immunity, there was no correlation between anti-vector immunity in Ad26.COV2.S recipients and spike-specific neutralizing antibody or T-cell responses post-Ad26.COV2.S boosting. Conclusion In the context of hybrid immunity, boosting with heterologous full- or half-dose BNT162b2 mRNA vaccine demonstrated superior immunogenicity 2 weeks post-vaccination compared to homologous Ad26.COV2.S, though rapid waning occurred by 12 weeks post-boost. Trial Registration South African National Clinical Trial Registry (SANCR): DOH-27-012022-7841 Funding South African Medical Research Council (SAMRC) and South African Department of Health (SA DoH).


  • Open Access

    Blood and Site of Disease Inflammatory Profiles Differ in Patients With Pericardial Tuberculosis and Human Immunodeficiency Virus Type 1

    by Hygon Mutavhatsindi, Elsa Du Bruyn, Sheena Ruzive, Patrick Howlett, Maddalena Cerrone, Alan Sher, Katrin D Mayer-Barber, Daniel L Barber, Mpiko Ntsekhe, Robert J Wilkinson, et al.

    Background: To better understand the pathogenesis of pericardial tuberculosis (PCTB), we sought to characterize the systemic inflammatory profile in people with human immunodeficiency virus type 1 (HIV-1) with latent TB infection (LTBI), pulmonary TB (PTB), or PCTB.Methods: Using Luminex, we measured the concentration of 39 analytes in pericardial fluid (PCF) and paired plasma from 18 PCTB participants, and plasma from 16 LTBI and 20 PTB participants. Follow-up plasma samples were also obtained from PTB and PCTB participants. HLA-DR expression on Mycobacterium tuberculosis–specific CD4 T cells was measured in baseline samples using flow cytometry.Results: Assessment of the overall systemic inflammatory profile by principal component analysis showed that the inflammatory profile of active TB participants was distinct from the LTBI group, while PTB patients could not be distinguished from those with PCTB. When comparing the inflammatory profile between PCF and paired blood, we found that the concentrations of most analytes (25/39) were elevated at site of disease. However, the inflammatory profile in PCF partially mirrored inflammatory events in the blood. After TB treatment completion, the overall plasma inflammatory profile reverted to that observed in the LTBI group. Lastly, HLA-DR expression showed the best performance for TB diagnosis compared to previously described biosignatures built from soluble markers.Conclusions: Our results show that the inflammatory profile in blood was comparable between PTB and PCTB. However, at the site of infection (PCF), inflammation was significantly elevated compared to blood. Additionally, our data emphasize the potential role of HLA-DR expression as a biomarker for TB diagnosis.


  • Open Access

    Blood and site of disease inflammatory profiles differ in HIV-1-infected pericardial tuberculosis patients

    by Hygon Mutavhatsindi, Elsa Du Bruyn, Sheena Ruzive, Patrick Howlett, Alan Sher, Katrin D. Mayer-Barber, Daniel L. Barber, Mpiko Ntsekhe, Robert J. Wilkinson, Catherine Riou

    Objectives To better understand the pathogenesis of pericardial tuberculosis (PCTB), we sought to characterize the systemic inflammatory profile in HIV-1-infected participants with latent TB infection (LTBI), pulmonary TB (PTB) and PCTB. Methods Using Luminex, we measured 39 analytes in pericardial fluid (PCF) and paired plasma from 18 PCTB participants, and plasma from 16 LTBI and 20 PTB. Follow-up plasma samples were also obtained from PTB and PCTB participants. HLA-DR expression on Mtb-specific CD4 T cells was measured in baseline samples using flow cytometry. Results Assessment of the overall systemic inflammatory profile by principal component analysis showed that the inflammatory profile of active TB participants was distinct from the LTBI group, while PTB patients could not be distinguished from those with PCTB. In the LTBI group, 12 analytes showed a positive association with plasma HIV-1 viral load, and most of these associations were lost in the diseased groups. When comparing the inflammatory profile between PCF and paired blood, we found that the concentrations of most analytes (24/39) were elevated at site of disease. However, the inflammatory profile in PCF partially mirrored inflammatory events in the blood. After TB treatment completion, the overall plasma inflammatory profile reverted to those observed in the LTBI group. Lastly, HLA-DR expression showed the best performance for TB diagnosis compared to previously described biosignatures built from soluble markers. Conclusion Our results describe the inflammatory profile associated with PTB and PCTB and emphasize the potential role of HLA-DR as a promising biomarker for TB diagnosis.

  • Open Access

    Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity

    by Catherine Riou, Roanne Keeton, Thandeka Moyo-Gwete, Tandile Hermanus, Prudence Kgagudi, Richard Baguma, Ziyaad Valley-Omar, Mikhail Smith, Houriiyah Tegally, Deelan Doolabh, et al.

    SARS-CoV-2 variants that escape neutralization and potentially affect vaccine efficacy have emerged. T cell responses play a role in protection from reinfection and severe disease, but the potential for spike mutations to affect T cell immunity is incompletely understood. We assessed neutralizing antibody and T cell responses in 44 South African COVID-19 patients either infected with the Beta variant (dominant from November 2020 to May 2021) or infected before its emergence (first wave, Wuhan strain) to provide an overall measure of immune evasion. We show that robust spike-specific CD4 and CD8 T cell responses were detectable in Beta-infected patients, similar to first-wave patients. Using peptides spanning the Beta-mutated regions, we identified CD4 T cell responses targeting the wild-type peptides in 12 of 22 first-wave patients, all of whom failed to recognize corresponding Beta-mutated peptides. However, responses to mutated regions formed only a small proportion (15.7%) of the overall CD4 response, and few patients (3 of 44) mounted CD8 responses that targeted the mutated regions. Among the spike epitopes tested, we identified three epitopes containing the D215, L18, or D80 residues that were specifically recognized by CD4 T cells, and their mutated versions were associated with a loss of response. This study shows that despite loss of recognition of immunogenic CD4 epitopes, CD4 and CD8 T cell responses to Beta are preserved overall. These observations may explain why several vaccines have retained the ability to protect against severe COVID-19 even with substantial loss of neutralizing antibody activity against Beta.


  • Identification of novel salivary candidate protein biomarkers for tuberculosis diagnosis: A preliminary biomarker discovery study

    by Hygon Mutavhatsindi, Bridget Calder, Shirley McAnda, Stephanus T. Malherbe, Kim Stanley, Martin Kidd, Gerhard Walzl, Novel N. Chegou


  • Open Access

    Serum and cerebrospinal fluid host proteins indicate stroke in children with tuberculous meningitis

    by Charles M. Manyelo, Novel N. Chegou, James A. Seddon, Candice I. Snyders, Hygon Mutavhatsindi, Portia M. Manngo, Gerhard Walzl, Kim Stanley, Regan S. Solomons

    Introduction: Stroke is a common complication in children with tuberculous meningitis (TBM). Host proteins may give us insight into the mechanisms of stroke in TBM and serve as biomarkers for detection of stroke, however, they have not been widely explored. In this study, we compared the concentrations of cerebrospinal fluid (CSF) and serum proteins between children who had TBM-related stroke and children with TBM without stroke. Methods: We collected CSF and serum from 47 children consecutively admitted to the Tygerberg Academic Hospital in Cape Town, South Africa between November 2016, and November 2017, on suspicion of having TBM. A multiplex platform was used to measure the concentrations of 69 host proteins in CSF and serum from all study participants. Results: After classification of study participants, 23 (48.9%) out of the 47 study participants were diagnosed with TBM, of which 14 (60.9%) demonstrated radiological arterial ischemic infarction. The levels of lipocalin-2, sRAGE, IP-10/ CXCL10, sVCAM-1, MMP-1, and PDGF-AA in CSF samples and the levels of D-dimer, ADAMTS13, SAA, ferritin, MCP-1/ CCL2, GDF-15 and IL-13 in serum samples were statistically different between children who had TBM-related stroke and children with TBM without stroke. After correcting for multiple testing, only the levels of sVCAM-1, MMP-1, sRAGE, and IP-10/ CXCL10 in CSF were statistically different between the two groups. CSF and serum protein biosignatures indicated stroke in children diagnosed with TBM with up to 100% sensitivity and 88.9% specificity. Conclusion: Serum and CSF proteins may serve as biomarkers for identifying individuals with stroke amongst children diagnosed with TBM at admission and may guide us to understand the biology of stroke in TBM. This was a pilot study, and thus further investigations in larger studies are needed.